Indications:
Dinoglandin E2 Vaginal Tablets are indicated for the induction of labour,
especially in patients with favourable induction features, when there
are no fetal or maternal contra-indications.

Dosage:

One tablet (3 mg) to be inserted high into the posterior fornix. A second tablet may be inserted after six to eight hours if labour is not established, maximum dose 6 mg.

Side effect:
The most commonly reported events are vomiting, nausea, and diarrhea.
Certain rare events that should be especially noted are: hypersensitivity
to the drug; uterine rupture and cardiac arrest. Other adverse events,
in decreasing order of severity, reported with use of Dinoprostone, are
pulmonary /amniotic fluid embolism; abruption placenta; still birth,
neonatal death; uterine hyper contractility or hypertonous; fetal
distress; hypertension-systematic (maternal); bronchospasm
/asthma; rapid cervical dilation; fever; back ache; rash; vaginal
symptoms – warmth, irritation, pain.In addition, other adverse
reactions that have been seen with the use of prostaglandinE2
for term labour induction have included: altered fetal heart rate
patterns; uterine hyper contractility with fetal bradycardia, uterine
hyper contractility without fetal bradycardia and low Apgar scores
in the newborn.

Drug interaction:
Since it has been found that prostaglandins potentiate the effect
of oxytocin, it is not recommended that these drugs are used
together. If used in sequence, the patient’s uterine activity should
be carefully monitored.
Pregnancy and lactation:
Dinoglandin E2 Vaginal Tablets are only used during pregnancy,
to induce labour.
Prostaglandins are excreted in breast milk. This is not expected
to be a hazard given the circumstances in which the product is used

Packages:
Carton box containing 1, 2, 3, 4 & 5 (PVC/PVDC/AL) strips, each
of 2 tablets with inner leaflet.

Download Dinoglandin E2 Flyer(PDF)